Article
Splice variants of androgen receptor and prostate cancer
30 May 2016
Abstract excerpt
Over the last ten years, two new-generation hormonal drugs and two chemotherapeutic agents have been approved for the treatment of metastatic castration-resistant prostate cancer. Unfortunately, some patients have primary resistance to them and the others eventually develop secondary resistance. It has recently been suggested that the presence of androgen receptor splice variants plays a leading role in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
